This collaboration marks a significant step in both companies’ efforts to address the pressing needs in cancer treatment through innovative solutions.

OBT has developed a proprietary discovery platform, OGAP-Verify, which has enhanced sensitivity and specificity for identifying promising drug targets.

This platform is central to collaboration, as it allows for selecting targets with improved attributes crucial for effective drug development.